Jefferies Group’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-48,424
| Closed | -$682K | – | 1611 |
|
|
2022
Q2 | $682K | Buy |
+48,424
| New | +$904K | 0.01% | 902 |
|
|
2021
Q2 | – | Sell |
-6,572
| Closed | -$170K | – | 1624 |
|
|
2021
Q1 | $170K | Sell |
6,572
-19,197
| -74% | -$845K | ﹤0.01% | 1382 |
|
|
2020
Q4 | $1.38M | Buy |
25,769
+23,395
| +985% | +$1.16M | 0.01% | 829 |
|
|
2020
Q3 | $98K | Buy |
2,374
+800
| +51% | +$34.5K | ﹤0.01% | 1246 |
|
|
2020
Q2 | $76 | Sell |
1,574
-227
| -13% | -$10.9K | ﹤0.01% | 1136 |
|
|
2020
Q1 | $74K | Buy |
+1,801
| New | +$74.2K | ﹤0.01% | 1833 |
|
|
2019
Q4 | – | Sell |
-30,780
| Closed | -$1.11M | – | 2510 |
|
|
2019
Q3 | $1.11M | Buy |
+30,780
| New | +$933K | 0.01% | 1448 |
|
|
2018
Q4 | – | Sell |
-17,258
| Closed | -$358K | – | 2115 |
|
|
2018
Q3 | $358K | Buy |
+17,258
| New | +$272K | ﹤0.01% | 1779 |
|
|
2018
Q1 | – | Sell |
-88,500
| Closed | -$2.67M | – | 2192 |
|
|
2017
Q4 | $2.67M | Sell |
88,500
-18,200
| -17% | -$582K | 0.01% | 842 |
|
|
2017
Q3 | $4.02M | Buy |
106,700
+60,700
| +132% | +$1.97M | 0.03% | 618 |
|
|
2017
Q2 | $1.28M | Buy |
46,000
+5,333
| +13% | +$159K | 0.01% | 1172 |
|
|
2017
Q1 | $1.4M | Buy |
40,667
+25,606
| +170% | +$904K | 0.01% | 1094 |
|
|
2016
Q4 | $434K | Buy |
15,061
+4,424
| +42% | +$117K | ﹤0.01% | 1642 |
|
|
2016
Q3 | $338K | Sell |
10,637
-2,403
| -18% | -$81.5K | ﹤0.01% | 1771 |
|
|
2016
Q2 | $423K | Sell |
13,040
-21,260
| -62% | -$711K | ﹤0.01% | 1515 |
|
|
2016
Q1 | $959K | Buy |
34,300
+28,600
| +502% | +$624K | 0.01% | 1161 |
|
|
2015
Q4 | $203K | Sell |
5,700
-30,353
| -84% | -$1.07M | ﹤0.01% | 1939 |
|
|
2015
Q3 | $1.19M | Buy |
36,053
+6,471
| +22% | +$269K | 0.01% | 1135 |
|
|
2015
Q2 | $1.24M | Buy |
29,582
+13,982
| +90% | +$541K | 0.01% | 1149 |
|
|
2015
Q1 | $508K | Buy |
15,600
+2,600
| +20% | +$89.4K | ﹤0.01% | 1372 |
|
|
2014
Q4 | $413K | Sell |
13,000
-2,000
| -13% | -$56.7K | ﹤0.01% | 1368 |
|
|
2014
Q3 | $371K | Sell |
15,000
-7,020
| -32% | -$164K | ﹤0.01% | 1481 |
|
|
2014
Q2 | $498K | Sell |
22,020
-238
| -1% | -$4.97K | ﹤0.01% | 1239 |
|
|
2014
Q1 | $542K | Sell |
22,258
-52,347
| -70% | -$1.32M | 0.01% | 1215 |
|
|
2013
Q4 | $1.86M | Buy |
74,605
+24,205
| +48% | +$571K | 0.01% | 602 |
|
|
2013
Q3 | $1.38M | Sell |
50,400
-12,104
| -19% | -$253K | 0.01% | 764 |
|
|
2013
Q2 | $1.14M | Buy |
+62,504
| New | +$861K | 0.01% | 714 |
|
Other funds holding ACAD
BBA
EC
RI
Jefferies Group's ACAD Position: Q3 2022 in Review
Jefferies Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 48,424 shares — an estimated $682K sold.
Jefferies Group first reported a position in ACAD in Q2 2013 and held it in 27 quarters. The position peaked at $4.02M in Q3 2017. 222 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.
- Jefferies Group reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
- Jefferies Group sold 48,424 Acadia Pharmaceuticals shares in Q3 2022, an estimated $682K.
- Jefferies Group first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Jefferies Group's Acadia Pharmaceuticals position peaked at $4.02M in Q3 2017.
- 222 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.
Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.